About Us

Management

Our founders, management, are globally acknowledged scientific and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Chief Executive Officer and Founder
READ MORE

Brice Suire

Chief Financial Officer and Founder
READ MORE

Didier Hagenauer

Director Clinical Development
READ MORE

Simone Dertschnig

Research Director
READ MORE

Supervisory Board

Our supervisory board is composed of venture capital leaders from leading international venture funds, also joined by Dr. Dhaval Patel, leader in S1Pr drug developments (Gilenya).

Manus Rogan

Chair
READ MORE

Dhaval Patel

Director
READ MORE

Marten Steen

Director
READ MORE

Henry Skinner

Director
READ MORE

Lionel Carnot

Director
READ MORE

Advisory Board

Christoph Bucher

Head of Clinical Advisory Board
READ MORE

Simone Seiter

Head of Commercial and Scientific Advisory Board
READ MORE

Investors Funds

Contact Us

Priothera Ltd
88 Harcourt Street, Dublin 2, D02 DK18, Ireland

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

Priothera SAS France
9 Rue du Temple, Saint Louis, 68300, France

Florent Gros

Chief Executive Officer and Founder

Florent Gros is CEO and Founder of Priothera. He has held various leadership positions in venture, intellectual property and transaction matters at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America. Florent is a Kaufmann Fellow, a certified European Patent Attorney, and he holds two master’s degrees, in Biotechnology Engineering and Private Law. At Novartis Venture Funds, Florent led investments and served in 17 start-up companies, of which 12 were exited. Since 2019, Florent is also Founder and CEO of Handl Therapeutics, a gene therapy company focusing on AAV-based neurodegenerative therapies.

Brice Suire

Chief Financial Officer and Founder

Brice has over 25 years’ financial experience in the life science sector, having worked as CFO and Financial consultant for several biotech and medtech companies including Gensight, Vivet and Oculis. Before that he worked for over 15 years at Novartis in Finance positions of increasing responsibility, including as Global Head of Finance Supply Chain Pharma. Prior to that, Brice played a significant role in establishing the Novartis Institute for Biomedical Research in Cambridge, MA, where he worked as Head of Finance for Research Collaborations and Global Head of Financial Reporting and Accounting for Research (at 6 different Novartis sites). Brice started his career with Audit Consultancy firms Mazars in Paris and London and Price Waterhouse Coopers in Madrid. He has a Master’s in Finance from Paris Dauphine, CPA, an IEP from INSEAD, and completed the Novartis Harvard Finance Leadership Program at Harvard Business School.

Didier Hagenauer

Director Clinical Development

Didier has more than 25 years of experience in clinical development, bringing extensive international experience in Medical Affairs in oncology and hematology from various companies, including AstraZeneca. He joins Priothera from Glycostem Therapeutics, a clinical stage company involved in the development of immunotherapy products for acute myelogenous leukemia, where he was Chief Medical Officer. Prior to that, Didier was at Kiadis Pharma, a European biopharmaceutical company, where he led the clinical development program of the Company’s lead program, an adjuvant therapy for hematopoietic stem cell transplantation in various leukemias and genetic diseases. Didier graduated as a Medical Doctor from the University of Paris, France and obtained his Business Administration degree from ESSEC, Paris.

Simone Dertschnig

Research Director

Simone holds a PhD in biomedical research/immunology from the University of Basel and has extensive research experience in the field of hematopoietic stem cell transplantation, graft-versus-host disease and transplantation immunology. She acquired her deep expertise in this area while conducting research at University of Basel and University College London, where she held research grants from the Swiss National Science Foundation, European Hematology Association, and Novartis Foundation for medical-biological research. Throughout her research career, she has contributed to advance the understanding of hematopoietic stem cell transplantation.

Manus Rogan

Dr Manus Rogan is a Managing Partner and co-founder of Fountain Healthcare Partners. He has over 27 years of investment and operating experience in the life science sector in both the US and Europe. Manus earned a PhD in chemistry from the University of York (sponsored by GlaxoSmithKline) and an MBA from Trinity College Dublin.

Manus began his career in product development at GlaxoSmithkline in the UK and in 1996 joined Elan Corporation’s business development group. For four years he was responsible for licensing products and drug delivery technologies in Europe and Japan. In 2001, Manus joined Elan’s Corporate Venture Capital group in New York where he invested in private and public biotechnology companies. Investments included Sirna (acquired by Merck, 2006) and Beyond Genomics (IPO, 2011). In his 7 years at Elan, Manus concluded over twenty five investment and technology licensing transactions involving companies in the US, Europe and Japan.

Manus led Fountain’s investment in Innocoll Inc. and currently serves on the board of Neuromod Devices and PrioThera Ltd. He previously represented Fountain on the boards of Inflazome (acquired by Roche), Amarin Corporation, Opsona Therapeutics and Mainstay Medical (IPO, 2014). He was formerly Chairman of the Irish Venture Capital Association (‘IVCA’).

Dhaval Patel

Dhaval is an EVP and CSO of UCB, based in Brussels, Belgium. He received an MD and PhD (Microbiology and Immunology) from and further clinical training in Internal Medicine, Rheumatology, Allergy, and Clinical Immunology at Duke University. Prior to joining the industry in 2006, he was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. During a 10 year career at Novartis, he led Research in Europe and Autoimmunity, Transplantation and Inflammation Disease Area which developed the S1PR modulators fingolimid and siponimod as well as several other medicines. He was also an Entrepreneur in Residence at the Novartis Venture Fund, and serves on several biotechnology boards.

Marten Steen

Dr. Mårten Steen. Partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology licensing. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry. He is the author of numerous scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.

Henry Skinner

Dr. Henry Skinner is CEO of the AMR Action Fund, a partnership that was set up by a coalition of pharmaceutical companies, philanthropies, and the European Investment Bank, with the support of the WHO, that aims to strengthen and accelerate antibiotic development. Prior to joining the AMR Action Fund, Dr. Skinner was Senior Vice President, Venture at Tekla Capital Management, LLC, and served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.

Lionel Carnot

Lionel Carnot is a Partner at Earlybird. Before joining Earlybird in 2016, Lionel was a Managing Director at Bay City Capital after having been extensively involved in the firm’s activities as part of The Pritzker Organization. Prior to The Pritzker Organization, Lionel was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly and several sales and marketing positions at Sanofi-Aventis. He was also a strategy and management consultant to the biopharmaceutical industry at Booz Allen & Hamilton, and Accenture Strategic Services. Lionel holds an MBA with Distinction from INSEAD and an M.Sc. in Molecular Biology from the University of Geneva.

Christoph Bucher

Head of Clinical Advisory Board

Christoph is the CMO of Anaveon. Before Christoph was at Roche, where he led the transition to the late-stage development of Crovalimab, a complement C5 inhibitor. Before that, Christoph was at the Novartis Institutes for BioMedical Research, where he led programs in the stem cell transplant and complement system spaces and conducted trials in cell therapy. He obtained his medical degree and training in stem cell transplantation and internal medicine in Basel, and he completed his postdoc in the immunobiology of graft versus host and graft versus leukemia effects in Bruce Blazar’s group at the University of Minnesota. Christoph continues to practice hematology part-time at the University Hospital Basel.

Simone Seiter

Head of Commercial and Scientific Advisory Board

Simone is a Partner at Simon-Kucher & Partners, leading their Commercial Strategy Cluster within the Life Sciences division. Before joining the company, she was the global lead of IQVIA´s Brand & Commercial Strategy Team and lead their launch excellence platform. She is a board certified dermatologists and worked at the University hospitals in Heidelberg and Homburg in Germany, as well as at several dermatology clinics. She also worked as a postdoctoral fellow at the NIH. Simone specializes in strategic pharmaceutical commercialization, launch, and brand excellence, portfolio and lifecycle management, including go-to-market strategies, P&MA strategies, product lifecycle strategies, and orphan diseases. She has supported many of the current top 20 pharma companies in successfully developing and commercializing their healthcare innovations in Europe and the US. Simone has published a number of articles and white papers on launch excellence and coauthored the IQVIA Launch Excellence series.

About Us

Management

Our founders, management, are globally acknowledged scientific and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Brice Suire

Didier Hagenauer

Simone Dertschnig

Supervisory Board

Our supervisory board is composed of venture capital leaders from leading international venture funds, also joined by Dr. Dhaval Patel, leader in S1Pr drug developments (Gilenya).

Manus Rogan

Dhaval Patel

Marten Steen

Henry Skinner

Lionel Carnot

Advisory Board

Christoph Bucher

Simone Seiter

Investors Funds

Contact Us

Florent Gros

Chief Executive Officer​ and Founder

Brice Suire

Chief Financial Officer and Founder

Didier Hagenauer

Director Clinical Development

Simone Dertschnig

Research Director

Manus Rogan

Dhaval Patel

Marten Steen

Henry Skinner

Lionel Carnot

Christoph Bucher

Head of Clinical Advisory Board

Simone Seiter

Head of Commercial and Scientific Advisory Board

Chief Executive Officer and Founder